This year, the 2013 annual meeting of the American Society of Hematology (ASH) in New Orleans is potentially the meeting of the year with much new data emerging, not only on a multitude of products, but also many biotechs – big and small – not just Pharma.
Last week a chance event unexpectedly found me on the road for two days instead of feverishly browsing the ASH abstracts in real time for the first time in years. I’ve been attending the meeting since the mid 1990’s in various guises, so was quite sad not to be ‘present’ for moment they went live.
Nonetheless, I must pay tribute to the Twitter Bio community who merrily shared and discussed their favourite abstracts on various topics, which made finding and sorting relevant ones much easier and quicker than it might have been. In particular, Patrick Crutcher (@chasingthealpha) of Chimera Research Group did a sterling job of highlighting many key sessions on Twitter, despite being on the west coast for a 9am open time. If you’re not following him on Twitter, check him out!
While reading through all the links and notes I collated, it made sense to write a series of preview posts on different topics. This year, I will be writing five preview posts, with a different topic highlighted in each one:
- Multiple Myeloma
- Chronic Lymphocytic Leukemia (CLL)
- Acute Leukemias
For today’s review of Myelofibrosis, the following companies and compounds will be covered:
Companies: Incyte, Novartis, Gilead, Sanofi, BMS, Geron, CTIC, Lilly, Celgene
Compounds: ruxolitinib, INCB039110, momelotinib, fedratinib, BMS-91143, imetelstat, pacritinib, LY2784544, pomalidomide, sonidegib
Note that not all of these agents are JAK inhibitors – others have a different target and can potentially be used in combination with a JAK inhibitor, some are pan JAK inhibitors, some selective and others dual inhibitors. This previews are really mini reviews of the abstracts, meaning it may be easier to print them out and read or contemplate over a cup of coffee.